Jim Cramer: MGM Resorts Has Good Top Management
On CNBC’s "Mad Money Lightning Round," Jim Cramer said MGM Resorts International (NYSE: MGM) has a lot of good top management.
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Biohaven And Pfizer Enter Strategic Collaboration For The Commercialization Of Rimegepant Outside The United States
Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) and Pfizer Inc. (NYSE:PFE), today announced a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval.
Biohaven Pharmaceutical Q3 EPS $(1.91) Beats $(2.40) Estimate, Sales $135.74M Beat $128.40M Estimate
Biohaven Pharmaceutical (NYSE:BHVN) reported quarterly losses of $(1.91) per share which beat the analyst consensus estimate of $(2.40) by 20.42 percent. This is a 28.46 percent increase over losses of $(2.67) per share
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
Biohaven Reports Enrollment Of Phase 1a/1b Trial Of BHV-110 In Combo With Natural Killer Cell Therapy For Treatment Of Multiple Myeloma
-- Biohaven initiates a clinical trial of the novel antibody recruiting molecule BHV-1100 to assess safety, tolerability, and exploratory clinical activity in Multiple Myeloma
-- BHV-1100 targets the destruction of
Analyst Ratings For Biohaven Pharma Hldgs
Within the last quarter, Biohaven Pharma Hldgs (NYSE:BHVN) has observed the following analyst ratings:
Where Biohaven Pharma Hldgs Stands With Analysts
Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE:BHVN) within the last quarter:
Goldman Sachs Maintains Buy on Biohaven Pharma Hldgs, Raises Price Target to $170
Goldman Sachs analyst Paul Choi maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Buy and raises the price target from $151 to $170.